Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.

导出原文传递

翻译打印收藏纠错

作者： Johann S,de Bono ^[1] ; Ugo,De Giorgi ^[2] ; Daniel Nava,Rodrigues ^[3] ; Christophe,Massard ^[4] ; Sergio,Bracarda ^[5] ; Albert,Font ^[6] ; Jose Angel,Arranz Arija ^[7] ; Kent C,Shih ^[8] ; George Daniel,Radavoi ^[9] ; Na,Xu ^[10] ; Wai Y,Chan ^[10] ; Han,Ma ^[10] ; Steven,Gendreau ^[10] ; Ruth,Riisnaes ^[3] ; Premal H,Patel ^[10] ; Daniel J,Maslyar ^[10] ; Viorel,Jinga ^[9]

作者单位： The Royal Marsden/Institute of Cancer Research, London, United Kingdom. Johann.DeBono@icr.ac.uk. ^[1] Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, (IRST) IRCCS, Meldola, Italy. ^[2] The Royal Marsden/Institute of Cancer Research, London, United Kingdom. ^[3] Institut Gustave Roussy, Villejuif, France. ^[4] Medical Oncology, Ospedale San Donato, Azienda USL Toscana Sud-Est, Istituto Toscano Tumori, Arezzo, Italy. ^[5] Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain. ^[6] Hospital General Universitario Gregorio Marañón, Madrid, Spain. ^[7] Tennessee Oncology, Nashville, Tennessee. ^[8] Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. ^[9] Genentech, Inc., South San Francisco, California. ^[10]